Clinical relevance of lung-restricted antibodies in lung transplantation

Mahzad Akbarpour, Qiang Wu, Xianpeng Liu, Haiying Sun, Emilia Lecuona, Rade Tomic, Sangeeta Bhorade, Thalachallour Mohanakumar, Ankit Bharat*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

9 Scopus citations


Lung transplant is a definitive treatment for several end-stage lung diseases. However, the high incidence of allograft rejection limits the overall survival following lung transplantation. Traditionally, alloimmunity directed against human leukocyte antigens (HLA) has been implicated in transplant rejection. Recently, the clinical impact of non-HLA lung-restricted antibodies (LRA) has been recognized and extensive research has demonstrated that they may play a dominant role in the development of lung allograft rejection. The immunogenic lung-restricted antigens that have been identified include amongst others, collagen type I, collagen type V, and k-alpha 1 tubulin. Pre-existing antibodies against these lung-restricted antigens are prevalent in patients undergoing lung transplantation and have emerged as one of the predominant risk factors for primary graft dysfunction which limits short-term survival following lung transplantation. Additionally, LRA have been shown to predispose to chronic lung allograft rejection, the predominant cause of poor long-term survival. This review will discuss ongoing research into the mechanisms of development of LRA as well as the pathogenesis of associated lung allograft injury.

Original languageEnglish (US)
Pages (from-to)595-601
Number of pages7
JournalHuman Immunology
Issue number8
StatePublished - Aug 2019


  • Antibodies
  • Lung transplant
  • Rejection

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Clinical relevance of lung-restricted antibodies in lung transplantation'. Together they form a unique fingerprint.

Cite this